MX2019000925A - Proteinas biespecificas y metodo de su preparacion. - Google Patents

Proteinas biespecificas y metodo de su preparacion.

Info

Publication number
MX2019000925A
MX2019000925A MX2019000925A MX2019000925A MX2019000925A MX 2019000925 A MX2019000925 A MX 2019000925A MX 2019000925 A MX2019000925 A MX 2019000925A MX 2019000925 A MX2019000925 A MX 2019000925A MX 2019000925 A MX2019000925 A MX 2019000925A
Authority
MX
Mexico
Prior art keywords
heavy chain
domain
methods
bispecific protein
preparing same
Prior art date
Application number
MX2019000925A
Other languages
English (en)
Inventor
Kim Hoeon
Bae Sohyun
Original Assignee
Ibentrus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ibentrus Inc filed Critical Ibentrus Inc
Publication of MX2019000925A publication Critical patent/MX2019000925A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una proteína biespecífica y un método de su preparación, en que la mutación es introducida en cadenas pesadas y/o cadenas ligeras para incrementar la heterodimerización entre una cadena pesada (domino CH3 o Fc) y una cadena pesada (dominio CH3 o Fc) y la dimerización entre una cadena pesada (dominio CH1) y una cadena ligera, en que ambos se dirigen al mismo material, de forma a construir proteínas biespecíficas heterodiméricas con alta pureza. Las proteínas biespecíficas según la presente invención pueden encontrar aplicaciones en una serie de campos que comprenden la terapia del cáncer, regulación de selección, diagnósticos etc.
MX2019000925A 2016-07-19 2017-07-19 Proteinas biespecificas y metodo de su preparacion. MX2019000925A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160091157 2016-07-19
PCT/KR2017/007791 WO2018016881A1 (ko) 2016-07-19 2017-07-19 이중 특이성 단백질 및 이의 제조 방법

Publications (1)

Publication Number Publication Date
MX2019000925A true MX2019000925A (es) 2019-06-03

Family

ID=60992392

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000925A MX2019000925A (es) 2016-07-19 2017-07-19 Proteinas biespecificas y metodo de su preparacion.

Country Status (16)

Country Link
US (1) US20230075499A1 (es)
EP (1) EP3489262A4 (es)
JP (2) JP2019530641A (es)
KR (4) KR102098919B1 (es)
CN (2) CN109476763B (es)
AU (2) AU2017298535B2 (es)
BR (1) BR112019001138A2 (es)
CA (2) CA3031082C (es)
IL (1) IL264249B2 (es)
MX (1) MX2019000925A (es)
MY (1) MY200137A (es)
PH (1) PH12019500138A1 (es)
RU (1) RU2745648C2 (es)
SG (1) SG11201900373WA (es)
WO (1) WO2018016881A1 (es)
ZA (1) ZA201900347B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
KR102398736B1 (ko) * 2011-10-31 2022-05-16 추가이 세이야쿠 가부시키가이샤 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
EA202090641A1 (ru) * 2017-09-29 2020-08-07 Чугаи Сейяку Кабусики Кайся Мультиспецифическая антиген-связывающая молекула, обладающая замещающей функциональной активностью кофактора коагулирующего фактора крови viii, и фармацевтическая композиция, содержащая указанную молекулу в качестве активного ингредиента
EP3946354A4 (en) * 2019-03-28 2023-01-11 Ab Studio Inc. HETEROMULTIMER PROTEINS AND METHODS OF USE THEREOF
EP3959244A1 (en) * 2019-04-25 2022-03-02 F. Hoffmann-La Roche AG Generation of antibody-derived polypeptides by polypeptide chain exchange
US20230265134A1 (en) * 2019-09-30 2023-08-24 Adimab, Llc Ch1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same
CN112646041B (zh) * 2019-10-12 2023-11-10 上海睿智化学研究有限公司 包含抗体ch3域的异源二聚体及含其的抗体、融合蛋白
CN113121696A (zh) * 2019-12-31 2021-07-16 周易 Fab改造诱导形成的双特异性抗体及其制备方法和用途
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
GB202005879D0 (en) * 2020-04-22 2020-06-03 Petmedix Ltd Heterodimeric proteins
CN116462766A (zh) * 2020-05-21 2023-07-21 美勒斯公司 用于生产ig样分子的方法和手段
KR102365669B1 (ko) 2020-06-01 2022-02-23 머스트바이오 주식회사 이중특이 항체 또는 그의 항원-결합 단편 및 이를 제조하는 방법
CN114437226A (zh) * 2020-11-05 2022-05-06 杭州菁因康生物科技有限公司 制备双特异性抗体的方法
WO2022115963A1 (en) * 2020-12-03 2022-06-09 Zymeworks Inc. Heterodimeric iga fc constructs and methods of use thereof
US20230116446A1 (en) * 2021-09-21 2023-04-13 Qilu Puget Sound Biotherapeutics Corporation HETERODIMERIC Fc FOR MAKING FUSION PROTEINS AND BISPECIFIC ANTIBODIES
CN117586413A (zh) * 2022-08-09 2024-02-23 三生国健药业（上海）股份有限公司 异多聚体蛋白质及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1899477A4 (en) * 2005-07-01 2010-01-20 Medimmune Inc INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTIC APPLICATIONS
CN101809037B (zh) * 2007-07-31 2014-01-15 瑞泽恩制药公司 人cd20的人抗体及其使用方法
ES2526887T3 (es) * 2007-12-14 2015-01-16 Bristol-Myers Squibb Company Método para producir moléculas de unión al receptor OX40 humano
PL2235064T3 (pl) * 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
US20130177555A1 (en) * 2010-08-13 2013-07-11 Medimmune Limited Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use
CN103429620B (zh) * 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
JP2014510084A (ja) 2011-03-17 2014-04-24 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 二重特異性および単一特異性の非対称な抗体ならびにそれらの作製方法
CN108285488B (zh) * 2011-03-25 2023-01-24 伊克诺斯科学公司 异二聚体免疫球蛋白
EA016517B1 (ru) * 2011-04-05 2012-05-30 Федеральное Государственное Бюджетное Учреждение "Научно-Исследовательский Институт Эпидемиологии И Микробиологии Имени Почетного Академика Н.Ф. Гамалеи" Министерства Здравоохранения И Социального Развития Российской Федерации Рекомбинантная псевдоаденовирусная наночастица, фармацевтическая композиция для профилактики или терапии гриппа (варианты), способ профилактики или терапии гриппа
CA2832389A1 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
US10344050B2 (en) * 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
KR102398736B1 (ko) * 2011-10-31 2022-05-16 추가이 세이야쿠 가부시키가이샤 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
WO2013089496A1 (ko) * 2011-12-15 2013-06-20 (주)에이프로젠 H1n1-감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
AU2013258834B2 (en) * 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
DK2927321T3 (da) * 2012-11-27 2021-03-15 Univ Ajou Ind Academic Coop Found Ch3-domæne-variantpar der inducerer dannelse af heterodimer af tungkæde konstant region af antistof ved høj effektivitet, fremgangsmåde til fremstilling af samme, og anvendelse deraf
EP3620473A1 (en) * 2013-01-14 2020-03-11 Xencor, Inc. Novel heterodimeric proteins
EP3444278A1 (en) * 2013-02-26 2019-02-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
CN105229036B (zh) * 2013-03-13 2022-05-24 伊班绰斯有限责任公司 在疏水性相互作用位点内引入了静电相互作用的蛋白及其制备方法
KR102546875B1 (ko) * 2014-05-02 2023-06-26 모멘타 파머슈티컬스 인코포레이티드 공학처리된 ｆｃ 작제물과 관련된 조성물 및 방법
CN115043945A (zh) * 2014-10-31 2022-09-13 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
CN107406512A (zh) * 2014-11-26 2017-11-28 Xencor公司 结合cd3和cd38的异二聚体抗体
EP3223845B1 (en) * 2014-11-26 2021-05-19 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
US20160176969A1 (en) * 2014-11-26 2016-06-23 Xencor, Inc. Heterodimeric antibodies including binding to cd8
US10982008B2 (en) * 2014-12-05 2021-04-20 Merck Patent Gmbh Domain-exchanged antibody

Also Published As

Publication number Publication date
JP2019530641A (ja) 2019-10-24
ZA201900347B (en) 2020-05-27
CA3203613A1 (en) 2018-01-25
NZ750825A (en) 2021-03-26
KR20200042883A (ko) 2020-04-24
KR102207260B1 (ko) 2021-01-25
RU2019103238A (ru) 2020-08-19
KR20200042884A (ko) 2020-04-24
SG11201900373WA (en) 2019-02-27
RU2019103238A3 (es) 2020-08-19
JP7335634B2 (ja) 2023-08-30
AU2021200412A1 (en) 2021-03-18
EP3489262A1 (en) 2019-05-29
IL264249B2 (en) 2023-08-01
WO2018016881A1 (ko) 2018-01-25
IL264249B1 (en) 2023-04-01
KR20180009727A (ko) 2018-01-29
JP2021130690A (ja) 2021-09-09
CA3031082C (en) 2023-08-22
EP3489262A4 (en) 2020-07-08
CN109476763A (zh) 2019-03-15
PH12019500138A1 (en) 2019-11-04
KR20200042885A (ko) 2020-04-24
CN109476763B (zh) 2023-11-07
BR112019001138A2 (pt) 2019-04-30
AU2017298535B2 (en) 2020-12-10
IL264249A (es) 2019-03-31
KR102207261B1 (ko) 2021-01-25
US20230075499A1 (en) 2023-03-09
AU2017298535A1 (en) 2019-03-07
CA3031082A1 (en) 2018-01-25
KR102098919B1 (ko) 2020-04-23
CN117143247A (zh) 2023-12-01
RU2745648C2 (ru) 2021-03-30
MY200137A (en) 2023-12-08

Similar Documents

Publication Publication Date Title
PH12019500138A1 (en) Bispecific proteins and methods for preparing same
MX2021007320A (es) Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor.
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
PH12019502283A1 (en) Anti-lag3 antibodies
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
PH12018500363A1 (en) Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
PH12017500819A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
EA201990285A1 (ru) Гетеродимерные иммуноглобулиновые конструкции и способы их получения
SG10201900015XA (en) Bispecific cd33 and cd3 binding proteins
EA201890028A1 (ru) Антитело, связывающее cd3 человека
PH12019502602A1 (en) Polypeptides antagonizing wnt signaling in tumor cells
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
PH12019501104A1 (en) Novel anti-human muc1 antibody fab fragment
PH12017500094A1 (en) Novel anti-human tie-2 antibody
EA201492163A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ
MX2017001789A (es) Compuestos sustituidos por halogeno novedosos.
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
CY1122728T1 (el) Αντισωματα εναντι hpa-1a
WO2020128870A3 (en) Methods of producing heterodimeric antibodies
MX2017001788A (es) Compuestos sustituidos con halogeno novedosos.